Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 in Recurrent or Refractory CLL/SLL
NCT05959694Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2023; status: recruiting.
02
Drugs
TQB3909
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05959694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959694.